Holmannova Drahomira, Borsky Pavel, Andrys Ctirad, Hamakova Kvetoslava, Cermakova Eva, Poctova Gabriela, Fiala Zdenek, Smejkalova Jindra, Blaha Vladimir, Borska Lenka
Institute of Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic.
Department of Clinical Immunology and Allergology, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic.
Metabolites. 2022 Jul 26;12(8):688. doi: 10.3390/metabo12080688.
Psoriasis and metabolic syndrome (MetS), a common comorbidity of psoriasis, are associated with mild chronic systemic inflammation that increases oxidative stress and causes cell and tissue damage. At the cellular level, chromosomal and DNA damage has been documented, thus confirming their genotoxic effect. The main objective of our study was to show the genotoxic potential of chronic inflammation and determine whether the presence of both pathologies increases chromosomal damage compared to psoriasis alone and to evaluate whether there are correlations between selected parameters and chromosomal aberrations in patients with psoriasis and MetS psoriasis. Clinical examination (PASI score and MetS diagnostics according to National Cholesterol Education Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; NCE/ATPIII criteria), biochemical analysis of blood samples (fasting glucose, total cholesterol, low density and high density lipoproteins; LDL, HDL, non-HDL, and triglycerides;TAG), DNA/RNA oxidative damage, and chromosomal aberration test were performed in 41 participants (20 patients with psoriasis without MetS and 21 with MetS and psoriasis). Our results showed that patients with psoriasis without metabolic syndrome (nonMetS) and psoriasis and MetS had a higher rate of chromosomal aberrations than the healthy population for which the limit of spontaneous, natural aberration was <2%. No significant differences in the aberration rate were found between the groups. However, a higher aberration rate (higher than 10%) and four numerical aberrations were documented only in the MetS group. We found no correlations between the number of chromosomal aberrations and the parameters tested except for the correlation between aberrations and HDL levels in nonMetS patients (rho 0.44; p < 0.02). Interestingly, in the MetS group, a higher number of chromosomal aberrations was documented in non-smokers compared to smokers. Data from our current study revealed an increased number of chromosomal aberrations in patients with psoriasis and MetS compared to the healthy population, especially in psoriasis with MetS, which could increase the genotoxic effect of inflammation and the risk of genomic instability, thus increasing the risk of carcinogenesis.
银屑病与代谢综合征（MetS）是银屑病常见的合并症，与轻度慢性全身性炎症相关，这种炎症会增加氧化应激并导致细胞和组织损伤。在细胞水平上，已记录到染色体和DNA损伤，从而证实了它们的遗传毒性作用。我们研究的主要目的是展示慢性炎症的遗传毒性潜力，并确定两种病症同时存在时与单独患银屑病相比是否会增加染色体损伤，以及评估银屑病合并MetS患者中选定参数与染色体畸变之间是否存在相关性。对41名参与者（20名无MetS的银屑病患者和21名合并MetS的银屑病患者）进行了临床检查（根据美国国家胆固醇教育成人高胆固醇检测、评估和治疗专家小组的标准进行银屑病面积和严重程度指数评分及MetS诊断；NCE/ATPIII标准）、血液样本的生化分析（空腹血糖、总胆固醇、低密度和高密度脂蛋白；LDL、HDL、非HDL和甘油三酯；TAG）、DNA/RNA氧化损伤以及染色体畸变测试。我们的结果表明，无代谢综合征的银屑病患者（非MetS）以及合并MetS的银屑病患者的染色体畸变率高于健康人群，健康人群的自发自然畸变率<2%。两组之间的畸变率未发现显著差异。然而，仅在MetS组记录到更高的畸变率（高于10%）和四个数值畸变。我们发现除了非MetS患者中畸变与HDL水平之间的相关性（rho 0.44；p<0.02）外，染色体畸变数量与所测试参数之间没有相关性。有趣的是，在MetS组中，与吸烟者相比，非吸烟者记录到的染色体畸变数量更多。我们当前研究的数据显示，与健康人群相比，银屑病合并MetS患者的染色体畸变数量增加，尤其是合并MetS的银屑病患者，这可能会增加炎症的遗传毒性作用和基因组不稳定的风险，从而增加致癌风险。
